Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

NCT ID: NCT02462967

Last Updated: 2020-10-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 162 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-06-30
• Study Completion Date: 2017-10-31

Brief Summary

Study GT 026 is a Phase 2, multicenter, parallel group, North American, randomized, placebo controlled, double blind study. This study will enroll subjects with portal hypertension (HVPG greater than or equal to 6 mm Hg) who also have a liver biopsy with cirrhosis (Ishak stage 5 or 6), presumably due to NASH, excluding subjects with medium and large varices and those with decompensated cirrhosis.

Subjects with portal hypertension and cirrhosis will be randomly assigned (1:1:1 ratio) to receive 1 of 3 treatment assignments including placebo, GR MD 02 in a dose of 2 mg/kg lean body mass, or GR MD 02 in a dose of 8 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 intravenous infusions. The primary endpoint analysis is the baseline adjusted change in HVPG at 1 year (53 55 weeks) in subjects treated with placebo as compared to subjects treated with GR MD 02 (2 mg/kg/week or 8 mg/kg/week).

An esophagogastroduodenoscopy (EGD) with evaluation for varices, HVPG, and liver biopsy will be performed before the first infusion and after the final 26th dose of the investigational medicinal product (IMP). Additionally, subjects will undergo a FibroScan (if available) prior to the first infusion, at Infusion Visit 13, and 14 to 28 days following final 26th infusion, an methacetin breath test (MBT), will be performed if available at screening, at Infusion Visit 13, and 14 to 28 days after the final infusion, and blood will be collected for assessment of biomarkers.

All subjects are to attend 2 postdose visits: the first will occur 14 to 28 days after the final dose administration and a second will occur 14 days following the first postdose visit.

Subjects will be offered enrollment into a subsequent separate study, an open label extension study, if there is adequate tolerability and no safety issues or signs of clinical progression that would recommend discontinuation.

Subjects who do not enroll in the open label extension study will be contacted via telephone every 6 months for 2 years and annually thereafter for a total of 4 years.

Conditions

Hypertension, Portal

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

2 mg/kg GR MD 02

GR MD 02 in a dose of 2 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 infusions

Group Type: ACTIVE_COMPARATOR

GR-MD-02

Intervention Type: DRUG

GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3

8 mg/kg GR MD 02

GR MD 02 in a dose of 8 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 infusions

Group Type: ACTIVE_COMPARATOR

GR-MD-02

Intervention Type: DRUG

GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3

Placebo

Phosphate buffered saline solution administered every other week over a 52 week period for a total of 26 infusions

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo for GR-MD-02

Interventions

GR-MD-02

GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3

Intervention Type: DRUG

Placebo

Placebo for GR-MD-02

Intervention Type: DRUG

Other Intervention Names

galactoarabino rhamnogalacturonate

Eligibility Criteria

Inclusion Criteria

1. Has a HVPG measurement ≥6 mm Hg.

2. Has a liver biopsy with cirrhosis (Ishak stage 5 or 6) presumably due to NASH. A liver biopsy diagnosis of cirrhosis presumably due to NASH will include the following 3 categories:

• Cirrhosis with a definitive pathological diagnosis of NASH (presence of fat, ballooning degeneration, and inflammation);
• Cirrhosis wherein the biopsy contains either fat (>5%) or ballooning hepatocytes with no evidence of viral hepatitis or other liver disease; or
• Cirrhosis with no evidence of viral hepatitis or other liver disease in a subject with at least a 5 year history of obesity (BMI ≥30) or at least a 5 year history of diabetes mellitus (as defined by diagnosis by a physician and treatment with at least 1 antidiabetic medication).

3. Is ≥18 years of age and ≤75 years of age at the time of screening.

4. Absence of hepatocellular carcinoma by valid imaging (liver ultrasound, triple phase computed tomography of liver or magnetic resonance imaging of liver) within 6 months prior to randomization. If there is not such test available, then it should be performed as part of standard of care.

5. Is willing and able to provide written informed consent prior to the initiation of any study specific procedures.

6. Is not pregnant and must have a negative serum pregnancy test result prior to randomization.

7. If a fertile man or woman participating in heterosexual relations, agrees to use effective means of contraception (ie, 2 effective methods of contraception, one of which must be a physical barrier method).

• Effective forms of contraception include condom, hormonal methods (birth control pills, injections or implants), diaphragm, cervical cap, or intrauterine device throughout his/her participation in this study and for 90 days after discontinuation of study treatment. Surgically sterile males and females are not required to use contraception provided they have been considered surgically sterile for at least 6 months. Surgical sterility includes history of vasectomy, hysterectomy, bilateral salpingo oophorectomy, or bilateral tubal ligation. Postmenopausal women who have been amenorrheic for at least 2 years at the time of screening will be considered sterile.

8. If a lactating woman, agrees to discontinue nursing before the start of study treatment and refrain from nursing until 90 days after the last dose of study treatment.

9. If a man, agrees to refrain from sperm donation throughout the study period and for a period of 90 days following the last dose of IMP. Female subjects may not begin a cycle of ova donation or harvest throughout the study period and for a period of 90 days following the last dose of IMP.

10. Prior to randomization, any subject on statins, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, or β 1 selective adrenergic receptor inhibitors should have been on a stable dose for at least 2 months and all attempts should be made to continue the subject on the same dose of the medication for the duration of study participation.

Exclusion Criteria

1. Has a history of hepatic decompensation including any episode of variceal bleeding, ascites not controlled by medication, or overt hepatic encephalopathy (defined by the clinical judgment of the principal investigator but shall include the presence of lethargy, disorientation, inappropriate behavior, and the presence of asterixis).

2. Has a presence of medium or large varices or varices with red signs regardless of size based on endoscopy.

• Small varices are defined by veins that occupy <25% of the distal one third of the esophageal lumen when insufflated. Veins that completely flatten upon insufflation of the esophagus are not conserved varices. Any varices larger than that are medium (up to 50%) or large (>50%).
• Red signs include red wale markings (dilated venules oriented longitudinally on the variceal surface), cherry red spots (small, red, spotty dilated venules usually approximately 2 mm in diameter on the variceal surface) or hematocystic spots (large, round, crimson red projection >3 mm that look like a blood blister on the variceal surface).

3. Has had a prior transjugular porto systemic shunt procedure.

4. Has evidence of other forms of chronic liver disease including viral hepatitis B or C, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson's disease, alpha 1 antitrypsin deficiency, alcoholic hepatitis, hemochromatosis, liver cancer, history of biliary diversion, or autoimmune hepatitis.

5. Has any of the following laboratory values:

• Serum alanine aminotransferase levels >10 × the upper limits of normal
• Serum aspartate aminotransferase levels >10 × the upper limits of normal
• Platelet count <60 000/mm3

*. Serum albumin ≤2.8 g/dL

• International normalized ratio (INR) ≥1.7
• Direct bilirubin ≥2.0 mg/dL
• Alpha fetoprotein >200 ng/mL

6. Has a Model End-Stage Liver Disease (MELD) score ≥15 or Child Turcotte Pugh Class B or C.

7. Has an estimated creatinine clearance of <50 mL/minute. Glomerular filtration rate will be estimated using the Cockcroft-Gault equation (Cockcroft 1976):

• Males: CrCl (mL/min) = ([140 - age] × weight) / (SCr × 72)
• Females: CrCl (mL/min) = ([140 - age]) × weight) / (SCr × 72)] × 0.85
• Where CrCl is creatinine clearance, age is in years, weight is in kg, and SCr is serum creatinine in mg/dL

8. Is unwilling or unable to safely undergo HVPG or liver biopsy.

9. Has known positivity for human immunodeficiency virus (HIV) infection or a positive HIV test result at screening.

10. Has had major surgery within 8 weeks of randomization, significant traumatic injury within 6 months, or anticipation of need for major surgical procedure during the course of the study.

11. Has a history of a solid organ transplant requiring current immunosuppression therapy.

12. Has used nonselective β adrenergic inhibitors within 6 weeks prior to randomization.

13. Has planned or anticipated variceal ligation therapy during the study.

14. Has had weight reduction surgery within the past 3 years or plans to undergo weight reduction surgery during the study.

15. Has current, significant alcohol consumption or a history of significant alcohol consumption for a period of more than 3 consecutive months any time within 1 year prior to screening.

• Significant alcohol consumption is defined as more than 20 grams per day in females and more than 30 grams per day in males. On average, a standard drink in the United States is considered to be 14 grams of alcohol, equivalent to 12 fluid ounces of regular beer (5% alcohol), 5 fluid ounces of table wine (12% alcohol), or 1.5 fluid ounces of 80 proof spirits (40% alcohol).

A score of ≥8 on the Alcohol Use Disorders Identification Test (AUDIT) (Babor 2000) will result in exclusion.

16. Has a positive urine screen result for amphetamines, cocaine, or nonprescription opiates (heroin, morphine) at screening.

17. Has clinically significant and uncontrolled cardiovascular disease (eg, uncontrolled hypertension, myocardial infarction within 6 months prior to randomization, unstable angina), New York Heart Association Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring devise/ablation or Grade II or greater peripheral vascular disease within 12 months prior to randomization.

18. Has a history of clinically significant hematologic, renal, hepatic, pulmonary, neurological, psychiatric, gastrointestinal, systemic inflammatory, metabolic or endocrine disorder or any other condition that, in the opinion of the investigator, renders the subject a poor candidate for inclusion into the study.

19. Has concurrent infection including diagnoses of fever of unknown origin at the time of randomization.

20. Has a history of malignancy, except for the following: adequately treated nonmetastatic basal cell skin cancer; any other type of skin cancer, except melanoma, that has been adequately treated and has not recurred for at least 1 year prior to enrollment; and adequately treated in situ cervical cancer that has not recurred for at least 1 year prior to screening.

21. Participates in an investigational new drug study within 30 days prior to randomization (including follow up visits) or at any time during the current study.

22. Has a clinically significant medical or psychiatric condition considered high risk for participation in an investigational study.

23. Fails to give informed consent.

24. Has known allergies to the IMP or any of its excipients.

25. Has previously received GR-MD-02 within 6 months of randomization.

26. Is an employee or family member of the investigator or study center personnel.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Dr. Naga Chalasani, MD, Indiana University

UNKNOWN

Sponsor Role: collaborator

Dr. Stephen A. Harrison, MD, Brooke Army Medical Center

UNKNOWN

Sponsor Role: collaborator

Galectin Therapeutics Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Cedars Sinai Medical Center

Los Angeles, California, United States

University of California Davis Medical Center

Sacramento, California, United States

University of California San Diego Medical Center

San Diego, California, United States

University of Colorado Denver

Aurora, Colorado, United States

University of Florida

Gainesville, Florida, United States

Florida Digestive Health Specialist

Lakewood Rch, Florida, United States

University of Miami

Miami, Florida, United States

IMIC

Palmetto Bay, Florida, United States

Tampa General Medical Group

Tampa, Florida, United States

Piedmont Hospital

Atlanta, Georgia, United States

Feinberg School of Medicine, Northwestern University

Chicago, Illinois, United States

Indiana University School of Medicine

Indianapolis, Indiana, United States

Tulane University Health Sciences Center

New Orleans, Louisiana, United States

Mercy Medical Center

Baltimore, Maryland, United States

Walter Reed National Military Medical Center

Bethesda, Maryland, United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

Henry Ford Health System

Detroit, Michigan, United States

Minnesota Gastroenterology PA

Saint Paul, Minnesota, United States

University of Mississippi Medical Center

Jackson, Mississippi, United States

Kansas City VA Medical Center

Kansas City, Missouri, United States

Saint Louis University

St Louis, Missouri, United States

North Shore University Hospital

Manhasset, New York, United States

Columbia University Medical Center

New York, New York, United States

Duke University Medical Center

Durham, North Carolina, United States

Digestive Health Specialists

Winston-Salem, North Carolina, United States

University Hospitals Case Medical Center

Cleveland, Ohio, United States

Hospital of The University of Pennsylvania

Philadelphia, Pennsylvania, United States

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

University Gastroenterology

Providence, Rhode Island, United States

Medical University of South Carolina

Charleston, South Carolina, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Texas Clinical Research Institute LLC

Arlington, Texas, United States

Texas Digestive Research Center

Dallas, Texas, United States

San Antonio Military Medical Center

Fort Sam Houston, Texas, United States

St Luke's Episcopal Hospital

Houston, Texas, United States

Pinnacle Clinical Research, PLLC

Live Oak, Texas, United States

Texas Liver Institute

San Antonio, Texas, United States

Intermountain Medical Center

Murray, Utah, United States

Mary Immaculate Hospital

Newport News, Virginia, United States

Digestive and Liver Disease Specialists

Norfolk, Virginia, United States

Bon Secours St. Mary's Hospital of Richmond

Richmond, Virginia, United States

Mcguire Veterans Affairs Medical Center

Richmond, Virginia, United States

Virginia Commonwealth University

Richmond, Virginia, United States

Swedish Medical Center

Seattle, Washington, United States

University of Washington

Seattle, Washington, United States

Countries

United States

References

Chalasani N, Abdelmalek MF, Garcia-Tsao G, Vuppalanchi R, Alkhouri N, Rinella M, Noureddin M, Pyko M, Shiffman M, Sanyal A, Allgood A, Shlevin H, Horton R, Zomer E, Irish W, Goodman Z, Harrison SA, Traber PG; Belapectin (GR-MD-02) Study Investigators. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. Gastroenterology. 2020 Apr;158(5):1334-1345.e5. doi: 10.1053/j.gastro.2019.11.296. Epub 2019 Dec 5.

Reference Type: RESULT

PMID: 31812510 (View on PubMed)

Are VS, Vuppalanchi R, Vilar-Gomez E, Chalasani N. Enhanced Liver Fibrosis Score Can Be Used to Predict Liver-Related Events in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis. Clin Gastroenterol Hepatol. 2021 Jun;19(6):1292-1293.e3. doi: 10.1016/j.cgh.2020.06.070. Epub 2020 Jul 3.

Reference Type: DERIVED

PMID: 32629127 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

GT-026

Identifier Type: -

Identifier Source: org_study_id